Lebok, Patrick, Huber, Julia, Burandt, Eike-Christian, Lebeau, Annette, Marx, Andreas Holger, Terracciano, Luigi, Heilenkoetter, Uwe, Jaenicke, Fritz, Mueller, Volkmar, Paluchowski, Peter, Geist, Stefan, Wilke, Christian, Simon, Ronald, Sauter, Guido and Quaas, Alexander (2016). Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer. Mol. Med. Rep., 14 (2). S. 1443 - 1451. ATHENS: SPANDIDOS PUBL LTD. ISSN 1791-3004
Full text not available from this repository.Abstract
Angiogenesis is a key process in tumor growth and progression, which is controlled by vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs). In order to better understand the prevalence and prognostic value of VEGFR1 expression in breast cancer, a tissue microarray containing >2,100 breast cancer specimens, with clinical follow-up data, was analyzed by immunohistochemistry using an antibody directed against the membrane-bound full-length receptor protein. The results demonstrated that membranous VEGFR1 staining was detected in all (5 of 5) normal breast specimens. In carcinoma specimens, membranous staining was negative in 3.1%, weak in 6.3%, moderate in 10.9%, and strong in 79.7% of the 1,630 interpretable tissues. Strong staining was significantly associated with estrogen receptor and progesterone receptor expression, but was inversely associated with advanced tumor stage (P=0.0431), high Bloom-Richardson-Ellis Score for Breast Cancer grade and low Ki67 labeling index (both P<0.0001). Cancers with moderate to strong (high) VEGFR1 expression were associated with significantly improved overall survival, as compared with tumors exhibiting negative or weak (low) expression (P=0.0015). This association was also detected in the subset of nodal-positive cancers (P=0.0018), and in the subset of 185 patients who had received tamoxifen as the sole therapy (P=0.001). In conclusion, these data indicated that membrane-bound VEGFR1 is frequently expressed in normal and cancerous breast epithelium. In addition, reduced or lost VEGFR1 expression may serve as a marker for poor prognosis in patients with breast cancer, who might not optimally benefit from endocrine therapy.
| Item Type: | Journal Article | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Creators: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| URN: | urn:nbn:de:hbz:38-268588 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DOI: | 10.3892/mmr.2016.5430 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Journal or Publication Title: | Mol. Med. Rep. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Volume: | 14 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Number: | 2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Page Range: | S. 1443 - 1451 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Date: | 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Publisher: | SPANDIDOS PUBL LTD | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Place of Publication: | ATHENS | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ISSN: | 1791-3004 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Language: | English | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Faculty: | Unspecified | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Divisions: | Unspecified | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Subjects: | no entry | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Uncontrolled Keywords: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Refereed: | Yes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| URI: | http://kups.ub.uni-koeln.de/id/eprint/26858 |
Downloads
Downloads per month over past year
Altmetric
Export
Actions (login required)
 |
View Item |